ClinicalTrials.gg

Program

lopinavir-ritonavir drug combination

Also written as “Lopinavir/Ritonavir”, “Lopinavir/ritonavir” and “lopinavir/ritonavir”.

Its studies are mostly in HIV Infections · Hepatitis C · Papilloma · Acquired Immunodeficiency Syndrome · Infections, led by 5 companies.

Furthest: phase 4, since Sep 13, 200517 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbott120 open or runningphase 4since Sep 13, 2005Nov 2, 1999none ahead
AbbVie20 open or runningphase 4since Sep 13, 2005Sep 13, 2005none ahead
Daré Bioscience11 open or runningphase 2since May 15, 2026May 15, 2026Oct 2027phase 2 · NCT07601074
virx10 open or runningphase 2since Nov 2, 1999Nov 2, 1999none ahead
World Medicine ILAC SAN. ve TIC. A.S.10 open or runningphase 1since May 5, 2020May 5, 2020none ahead

Also a collaborator on its studies: Basilea Pharmaceutica International and Shionogi.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 3 studies since Nov 2, 1999.

  1. Nov 2, 1999Phase 1 study in HIV InfectionsAbbott · NCT00004580 · United States
  2. Nov 2, 1999Phase 2 study in HIV InfectionsAbbott · NCT00004578 · 100 enrolled · United States
  3. May 29, 2002Phase 2 study in HIV InfectionsAbbott · NCT00038220 · 40 enrolled · United States
  4. Jun 3, 2002Phase 3 study in HIV InfectionsAbbott · NCT00038636 · 36 enrolled · United States, France, Spain
  5. Aug 15, 2002Phase 3 study in HIV InfectionsAbbott · NCT00043966 · 200 enrolled · United States, Australia, France and more
  6. Aug 15, 2002Phase 2 study in HIV InfectionsAbbott · NCT00043953 · 30 enrolled · United States, Canada
  7. Jan 6, 2004Phase 2 study in HIV InfectionsAbbott · NCT00075231 · 150 enrolled · United States
  8. Jul 14, 2005Phase 2 study in HIV InfectionsAbbott · NCT00121017 · 200 enrolled
  9. Sep 13, 2005AbbVie’s first study: phase 4 study in HIV InfectionsNew to AbbVieAbbVie · NCT00234975 · 86 enrolled · Puerto Rico
  10. Sep 13, 2005Phase 4 study in HIV InfectionsAbbott · NCT00234962 · 200 enrolled · United States
  11. Mar 28, 2008Phase 4 study in Acquired Immunodeficiency SyndromeAbbVie · NCT00648999 · 207 enrolled · Mexico
  12. Aug 27, 2008Phase 1 study in TuberculosisAbbott · NCT00743470 · 15 enrolled · United States
  13. May 5, 2020World Medicine ILAC SAN. ve TIC. A.S.’s first study: phase 1 study in BioequivalenceNew to World Medicine ILAC SAN. ve TIC. A.S.World Medicine ILAC SAN. ve TIC. A.S. · NCT04386876 · 30 enrolled · Turkey
  14. May 15, 2026Daré Bioscience’s first study: phase 2 study in Human Papilloma Virus (HPV)New to Daré BioscienceDaré Bioscience · NCT07601074 · 118 planned · United States

Ahead

  1. Oct 2027Primary completion: phase 2 study in Human Papilloma Virus (HPV)Daré Bioscience · NCT07601074

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 17 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07601074Human Papilloma Virus (HPV) · United States2RecruitingDaré BioscienceOct 2027118
NCT04386876Bioequivalence · Turkey1CompletedWorld Medicine ILAC SAN. ve TIC. A.S.May 22, 202030
NCT00743470Tuberculosis · United States1TerminatedAbbottOct 200815
NCT00648999Acquired Immunodeficiency Syndrome · Mexico4CompletedAbbVieDec 2006207
NCT00234975HIV Infections · Puerto Rico4CompletedAbbVieJan 200886
NCT00234962HIV Infections · United States4TerminatedAbbott200
NCT00121017HIV Infections2WithdrawnAbbott200
NCT00075231HIV Infections · United States2CompletedAbbott150
NCT00043966HIV Infections · United States, Australia, France and more3CompletedAbbott200
NCT00043953HIV Infections · United States, Canada2CompletedAbbott30
NCT00038636HIV Infections · United States, France, Spain3CompletedAbbott36
NCT00038220HIV Infections · United States2CompletedAbbott40
NCT00004583HIV Infections · United States, Australia, Austria and more3CompletedAbbott660
NCT00004582HIV Infections · United States2Completedvirx
NCT00004581HIV Infections · United States, Australia, Austria and more3CompletedAbbott300
NCT00004580HIV Infections · United States1CompletedAbbott
NCT00004578HIV Infections · United States2CompletedAbbottApr 2005100

How it is read

Names in the registry

  • “Lopinavir/Ritonavir”, 11 entries
  • “Lopinavir/ritonavir”, 7 entries
  • “lopinavir/ritonavir”, 3 entries
  • “Kaletra (lopinavir/ritonavir)”, 2 entries
  • “Lopinavir / ritonavir”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.